Summit Therapeutics shares are trading lower today, down roughly 3.6% to $24.79, in a move that appears driven more by positioning than by a new fundamental headline. A market recap of the prior day’s jump noted there was no fresh Summit press release or SEC filing that clearly explained the move, setting up today’s pullback as traders unwind a momentum bid. (quiverquant.com)

Summit’s valuation remains highly sensitive to ivonescimab milestones. The company has highlighted that the FDA accepted its BLA for ivonescimab in combination with chemotherapy in EGFR-mutant NSCLC after TKI therapy, with a stated PDUFA target action date of November 14, 2026—an event that keeps the stock in a catalyst-driven trading pattern. (finance.yahoo.com)

Near-term direction likely hinges on (1) the cadence of Phase III readouts and conference presentations, and (2) any incremental clarity on regulatory and clinical timelines that can reset expectations quickly. Separately, investors continue to monitor coverage shifts and price-target moves—such as Jefferies’ March 16, 2026 downgrade and sharp target cut—which can amplify day-to-day swings when there’s no new company-specific release. (investing.com)